Tel:400-875-6700
治疗实例

当前位置:首页 > 治疗实例 > 黑色素瘤> 逆转癌症的神奇靶向疗法

  • 逆转癌症的神奇靶向疗法

    化名:Mary Kate 年龄:49 病症:黑色素瘤
    就诊医院:哈佛大学医学院教学附属麻省总医院 返回上页

    患者参加了针对BRAF基因突变的靶向疗法临床试验,肿瘤缩小了75%,并成功地控制了黑色素瘤的进展。

    《郭军,中国黑色素瘤诊治指南2011版》与《美国国立癌症研究院(NCI)》数据显示:

    黑色素瘤发病率:中国1/10万,美国21/10万

    早中期黑色素瘤五年生存率:中国38-94%,美国达62.4-98%

    晚期黑色素瘤五年生存率:中国4.6%,美国达15.1%

    中国黑色瘤治疗第一人 

    2-1.jpg

    郭军教授

    北京肿瘤医院肾癌黑色素瘤内科主任

    国际黑色素瘤研究联盟委员

    简历:

    现任北京肿瘤医院、北京大学临床肿瘤学院副院长,北京市肿瘤防治研究所副所长,肾癌黑色素瘤内科主任。中国临床肿瘤协会(CSCO)执委会委员,中国临床肿瘤协会(CSCO)黑色素瘤专家委员会主任委员,中国临床肿瘤协会(CSCO)肾癌专家委员会主任委员,国际黑色素瘤研究联盟(Society for Melanoma Research)亚太地区主席,国际黑色素瘤基金会(MIF)海外咨询顾问。中国抗癌协会泌尿肿瘤分会常务委员《NCCN肾癌诊治指南中国版》执笔人,《中国黑色素瘤诊治共识》及《中国黑色素瘤诊治指南》编写组执笔人。临床擅长:肾癌、恶性黑色素瘤、膀胱癌、前列腺癌、肾上腺肿瘤综合治疗。

    近年发表的代表性论著(影响因子共61.64分)

    1. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. A Phase II, Open Label, Single-arm Trial of Imatinib Mesylate in Patients with Metastatic Melanoma Harboring c-Kit Mutation or Amplification. J Clin Oncol. 2011, June 20, 10.1200/JCO.2010.33.9275. (IF=18.96)

    2. Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, Tang B, Guo J. A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients. Eur J Cancer. 2011(47):1498-1503. (IF=4.943)

    3. Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer. 2011;11:85. (IF=3.153)

    4. Kong Y, Si L, Zhu Y, Xu XG, Corless CL, Flaherty K, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J. Large Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clin Cancer Res. 2011;17(7): 1684-1691. (IF=7.337)

    5. Si L, Kong Y, Xu X, Corless CL, Flaherty KT, Sheng X, Cui C, Chi Z, Zhu Y, Li S, Han M, Mao L, Guo J. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer.2011. (in press) (IF=4.943)

    6. Chen T, Guo J, Yang M, Zhu X, Cao X. Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. J Immunol. 2011;186:2219-28. (IF=5.745)

    7. Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182:1449-59. (IF=5.745)

    8. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P. Immunotherapy of distant metastatic disease. Ann Oncol. 2009 Aug; 20 Suppl 6:vi41-50. (IF=5.647)

    9. Lu Si, Zhi-hong Chi, Xiang-qing Yuan, Chuan-liang Cui, Xi-nan Sheng, Jun Guo. A phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma. Chinese Journal of Cancer Research,2009 Mar 21(1), 13-19. (IF=0.252)

    10. Guo J, Zhu J, Sheng X, Wang X, Qu L, Han Y, Liu Y, Zhang H, Huo L, Zhang S, Lin B, Yang Z. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer. 2007;120:2418-25. (IF=4.926)


    资料来源:北京肿瘤医院

    http://www.bjcancer.org/_Dept/DoctorView.aspx?id=57


    美国黑色素瘤治疗第一人

    2-2.jpg

    F. Stephen Hodi, Jr.

    国际黑色素瘤研究联盟创始人

    美国哈佛大学医学院附属布列根-丹娜法伯癌症中心黑色素瘤治疗中心主任

    美国哈佛大学医学院副教授

    美国NCCN黑色素瘤诊治指南制定者

    全球第一个研究人类恶性黑色素瘤的科学家

    简历:

    Hodi博士获美国内科医学和医学肿瘤学专业资格认证,拥有24年医学从业经验,是全球最大的黑色素瘤研究协会——国际黑色素瘤研究联盟的创始人,是全球第一个研究人类恶性黑色素瘤的科学家。美国NCCN (National Comprehensive Cancer Network)、美国临床肿瘤学会(ASCO)、美国东部肿瘤协作组黑色素瘤委员会和国际癌症生物治疗学会的委员。1998年获美国临床科学家发展奖。美国NCCN黑色素瘤诊治指南制定者(中国黑色素瘤诊治指南是通过参考美国NCCN黑色素瘤诊治指南修订而成)。是黑色素瘤基因治疗、免疫治疗领域的全球最权威专家。临床擅长:恶性黑色素瘤的靶向治疗和免疫治疗。

    近年发表的代表性论著(影响因子共782分)

    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28; 366(26):2443-54.( IF=53.298)

    2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8):711-23.( IF=53.298)

    3. Thompson JF, Hodi FS, Zembowicz A. Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm. N Engl J Med. 2007 Jan 18; 356(3):285-92. (IF=53.298)

    4. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012; 12(5):349-61. (IF= 37.545)

    5. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.  (IF=35.532)

    6. Reidenberg MM, Hodi FS. A plea for prices in physician prescribing. JAMA. 1991 Dec 18; 266(23):3285.(IF=30.026)

    7. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May; 13(5):459-65.  (IF=22.589)

    8. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 1; 26(13):2178-85.  (IF=18.372)

    9. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.  (IF=18.372)

    10. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998 Feb; 16(2):670-82.  IF=18.372

    11. Haluska FG, Hodi FS. . The molecular genetics of familial malignant melanoma. Journal of Clinical Oncology. 1998; 16:670-682.  IF=18.372

    12. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30.  IF=18.372

    13. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathiesen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. . Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. Journal of Clinical Oncology. 2003; 21:624-630.  IF=18.372 

    14. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. . Vaccination with Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony Stimulating Factor by Adenoviral Mediated Gene Transfer Augments Anti-tumor Immunity in Patients with Metastatic Melanoma. Journal of Clinical Oncology. 2003; 21:3343-3350.  IF=18.372

    15. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003 Sep 1; 21(17):3343-50.  IF=18.372

    16. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010 Sep 22; 102(18):1388-97.  IF=13.757

    17. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008 Apr; 222:287-98. IF=11.148

    18. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9190-5. IF=9.681

    19. Luke JJ, Hodi FS. Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. Clin Cancer Res. 2012 Jan 1; 18(1):9-14.  IF=7.742

    20. Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010 Jan 15; 70(2):697-708. IF=7.856

    21. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi MT, Landi TM, Sosman J. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res. 2010 Feb; 23(1):14-26. IF=5.059

    22. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1; 15(23):7412-20. IF=7.742

    23. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the "Melanoma Research: a bridge from Naples to the World. Napoli, December 5th-6 th2011". J Transl Med. 2012; 10:83.  IF=3.474

    24. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. J Natl Compr Canc Netw. 2012 Mar 1; 10(3):366-400.  IF=4.409

    25. Alloo A, Garibyan L, Leboeuf N, Lin G, Werchniak A, Hodi FS, Flaherty KT, Lawrence DP, Lin JY. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012 Mar; 148(3):363-6. IF= 3.888

    26. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma. PLoS One. 2012; 7(1):e29622. IF=4.092

    27. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, H?kansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011; 9(1):214. IF=3.474

    28. Zhou J, Yuen NK, Zhan Q, Velazquez EF, Murphy GF, Giobbie-Hurder A, Hodi FS. Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunol Immunother. 2012 May; 61(5):655-65. IF=3.701

    29. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol. 2011 Aug; 197(2):W241-6. IF=2.775

    30. Wu X, Zhou J, Rogers AM, J?nne PA, Benedettini E, Loda M, Hodi FS. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 2012 Apr; 22(2):123-32.  IF=2.187

    31. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011 Apr 27; 3(80):80ra34. IF=7.804

    32. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011 Jul 15; 17(14):4622-8. IF=7.742

    33. Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS, Dranoff G. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60. IF=7.856

    34. Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010 May; 22(3):178-83. IF=4.101

    35. Hodi FS, Dranoff G. The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol. 2010 Apr; 37 Suppl 1:48-53. IF=1.561

    36. Hodi FS. Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia Pac J Clin Oncol. 2010 Mar; 6 Suppl 1:S16-23. IF=0.585

    37. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK. Melanoma. J Natl Compr Canc Netw. 2009 Mar; 7(3):250-75. IF=4.409 

    38. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008 Dec 1; 14(23):7726-32. IF=7.742 

    39. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008 Nov 1; 14(21):6821-8. IF=7.742

    40. Hodi FS, Fisher DE. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol. 2008 Dec; 5(12):696-7. IF=8

    41. Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008 Aug; 32(8):1130-7. IF=4.352

    42.Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Day AL, Kruse A, Mac Rae S, Hoos A, Mihm M. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008 Sep; 5(9):557-61. IF=8

    43.Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, Salgia R, Giobbie-Hurder A, Dranoff G, Hodi FS. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008 Jun 15; 14(12):3896-905. IF=7.742

    44.Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, LaBaer J. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 2008 Apr; 7(4):1490-9. IF=5.113

    45.Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3005-10. IF=9.681 

    46.Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 1; 68(3):664-73. IF=7.856

    47.Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5238-42. IF=7.742

    48.Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007 Mar 15; 13(6):1857-67. IF=7.742

    49.Hodi FS. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res. 2006 Feb 1; 12(3 Pt 1):673-8. IF=7.742

    50.Hodi FS, Dranoff G. Combinatorial cancer immunotherapy. Adv Immunol. 2006; 90:341-68. IF=5.762

    51.Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101. IF=3.267

    52.Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res. 2005 Nov 1; 11(21):7692-9. IF=7.742

    53.Hodi FS, Granter S, Antin J. Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005; 5:7. IF=3.701 

    54.Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82. IF=2.187

    55.Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7. IF=9.681

    56.Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 Mar 17; 3:3. IF=3.701

    57.Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403. IF=9.681

    58.Schmollinger JC, Vonderheide RH, Hoar, KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, North PE, Mihm M, Kutok JL, Dranoff G. . The inhibitor of apoptosis protein ML-IAP is a target for immune mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:3398-3403. IF=9.681

    59.Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002 Sep 15; 100(6):2123-31. IF=9.898

    60.Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002 Jun; 25(3):283-6. IF=2.005

    61.Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol. 2002 Jun; 138(6):799-802. IF=3.888

    62.Hodi FS, Schmollinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, Alyea EP, Yang J, Neuberg D, Mihm M, Dranoff G. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24. IF=9.681

    63.Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls, AJ, Chessia M, Barrett P, Gribben JG. . Identification of novel antigens in chronic lymphocytic leukemia by SEREX: Assessment of their potential as targets for immunotherapeutic approaches. Blood. 2002; 100:2123-2131. IF=9.898

    64.Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45. IF=3.256

    65.Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13141-6. IF=9.681

    66.Hodi FS, Dranoff G. Genetically modified tumor cell vaccines. Surg Oncol Clin N Am. 1998 Jul; 7(3):471-85. IF=1.117

    67.Watkins DI, Chen ZW, Hughes AL, Hodi FS, Letvin NL. Genetically distinct cell populations in naturally occurring bone marrow-chimeric primates express similar MHC class I gene products. J Immunol. 1990 May 15; 144(10):3726-35. IF=5.788

    68.Watkins DI, Shadduck JA, Hodi FS, Stone ME, Letvin NL. Use of cDNA probes specific for the human MHC class II beta loci for tissue-typing nonhuman primates at their class II beta loci. Transplantation. 1989 Jul; 48(1):170-3. IF=4.003

    69.Watkins DI, Hodi FS, Letvin NL. A primate species with limited major histocompatibility complex class I polymorphism. Proc Natl Acad Sci U S A. 1988 Oct; 85(20):7714-8. IF=9.681

    70.Daniel MD, Letvin NL, Sehgal PK, Schmidt DK, Silva DP, Solomon KR, Hodi FS, Ringler DJ, Hunt RD, King NW, et al. Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. Int J Cancer. 1988 Apr 15; 41(4):601-8. IF=5.444

    71.Daniel MD, Letvin NL, Sehgal PK, Schmidt DK, Silva DP, Solomon KR, Hodi FS Jr, Ringler DJ, Hunt RD, King NW, Desrosiers RC. Prevalance of antibodies to three retroviruses in a captive colony of Macaque monkeys. International Journal of Cancer. 1988; 41:601-8. IF=5.444


    资料来源:美国哈佛大学医学院附属布列根-丹娜法伯癌症中心

    http://doctors.dana-farber.org/directory/profile.asp?pict_id=0000263


    国际黑色素瘤权威专家简介

    2-3.jpg

    全球最大的黑色素瘤研究协会——国际黑色素瘤研究联盟主席

    美国哈佛大学医学院附属麻省总医院癌症中心黑色素瘤治疗中心主任

    麻省总医院皮肤生物学研究中心主任

    美国哈佛大学医学院教授

    简历:

    Fisher教授获美国内科医学委员会内科医学专业资格认证,是全球公认的皮肤学研究专家、临床医生和知名学者,拥有27年的医学从业经验,其研究重点为从分子学和遗传学角度研究黑色素瘤和皮肤色素沉着的成因,其关于医学、儿科和肿瘤学的专科培训在哈佛大学医学院内得到广泛的推广。

    成功案例

    姓名: Mary Kate

    年龄:49

    当前诊断:4期黑色素瘤

    分子指纹图谱:BRAF突变

    现状:4年生存者

    童年时期,Mary Kate和她的兄弟姐妹们就喜欢穿着T恤,带着帽子,涂着防晒霜在海滩玩耍。他们的母亲很早就告诉他们红发白肤对阳光暴晒及皮肤癌更敏感些。Mary Kate长大后成了一名热心的园丁,在户外时她非常注意保护自己。但是最终一生的谨慎也还是没能战胜基因,44岁时,Mary Kate检查出患有黑色素瘤。现在,肿瘤基因或许是延缓甚至逆转她的癌症的关键。

    2005年的秋天,Mary Kate背上的一小颗痣检查结果显示对黑色素瘤呈阳性。尽管采用了免疫疗法,手术以及化疗,肿瘤还是扩散了。到2009年中,黑色素瘤通过淋巴系统扩散到 肺部和大脑,进展成了4期癌症。

    Mary Kate知道自己身处逆境,但是在丈夫Michael及4个孩子(7至15岁)的支持下,她也知道她需要尝试现有的任何治疗方案。在麻省总医院癌症中心肿 瘤专家Donald Lawrence的指导下,Mary Kate参加了一系列的临床试验,包括马里兰州贝塞斯达的美国国立癌症研究院的临床试验,但是效果都微乎其微。

    “今年一月份,我躺在马里兰州医院的病床上,”Mary Kate回忆说,“当时我接到Lawrence医生的电话,他想让我再次去麻省总医院参加一项新的临床试验,这项试验的早期结果表明效果很好。”

    癌症中心的医务工作者们在Mary Kate的肿瘤中发现了一种基因突变,这种基因突变对于针对BRAF突变的基因定位药物很敏感,而这种基因定位药物刚好能抑制肿瘤的生长。尽管她当时卧床不起,身 体很虚弱,但是自从参加这项新的临床试验以来,Mary Kate感觉好了很多。她仍记得当时用手指触摸颈部时,颈部的肿瘤明显变小了。8周后,扫描结果显示Mary Kate的肿瘤明显变小了,缩小了75%。

    这种口服药物的副作用(包括对阳光的敏感度及关节痛)非常小。Mary Kate说相比较而言,使用这种药物的所得远远大于所失去的。尽管她知道黑色素瘤以后还会复发 ,但是对于她已经取得的进展她非常感激,并且希望能研发出更多的基因定位药物来控制她的黑色素瘤的进展。

    今年夏天,Mary Kate全家打算在马萨诸塞州特鲁的海滩度假3周。像往常一样,她会用宽檐太阳帽和SPF70的防晒霜保护好自己和家人,并且定期找皮肤病专家做检查。尽 管她要在海滩房屋的阴凉处享受新鲜的空气,但是Mary Kate非常渴望听到惊涛拍岸的声音和孩子们在海滩嬉戏的欢笑声。

    附美国黑色素瘤患者生存率统计数据:

    2-4.jpg

    官方来源链接:http://seer.cancer.gov/statfacts/html/melan.html#survival